Atossa Therapeutics develops medicines for unmet medical needs in oncology, focusing on breast cancer in women. Lead candidate (Z)-endoxifen is in Phase II trials to treat and prevent breast cancer. The company also works on immunotherapy/chimeric antigen receptor therapy programs. Founded in 2008, Atossa is headquartered in Seattle, Washington.
| Indicator | Value |
|---|---|
| PER | 11.7 |
| EV/EBITDA | 2.8 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | 6.1% |
| Net Debt/EBITDA | -2.9 |